Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-15. ← Back to Evidence Library

Tirzepatide: what the evidence says

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

---

What is it?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it switches on the receptors for two gut hormones, GIP and GLP-1. It acts like those hormones, which tell the pancreas to release insulin after meals. It also reduces appetite. It is injected once a week. It stays in the body a long time. Its half-life (the time it takes for half of the drug to be cleared from the body) is about 5 days. ^R7

The FDA has approved it for: ^R7 - Mounjaro: blood-sugar control, with diet and exercise, in adults and children 10 and older with type 2 diabetes; and lowering the risk of heart attack, stroke and heart death in adults with type 2 diabetes at high risk of these events. - Zepbound: with a reduced-calorie diet and more activity, losing excess weight and keeping it off long term in adults with obesity, or with overweight plus at least one weight-related condition; and treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The Zepbound label says not to combine it with other tirzepatide products or any GLP-1 drug. ^R7

Does it work?

Human Weight: in SURMOUNT-1, adults with obesity or overweight (without diabetes) lost on average 15.0%, 19.5% and 20.9% of body weight at 72 weeks on the three tested doses, vs 3.1% on placebo (a dummy treatment). ^R2

Human Type 2 diabetes: in SURPASS-2, all three tirzepatide doses lowered HbA1c (average blood sugar) more than semaglutide (study arms in the study table) over 40 weeks (−2.01 to −2.30 points vs −1.86), and weight loss was greater. ^R2

Human Sleep apnea: in SURMOUNT-OSA (two trials, adults with moderate-to-severe OSA and obesity), breathing pauses per hour of sleep (AHI) fell by about 25 to 29 on tirzepatide vs about 5 on placebo at 52 weeks. ^R2

Human Heart risk: SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and heart disease to tirzepatide or dulaglutide (another GLP-1 drug already shown to cut heart events), not placebo. Over about 4 years, heart attack, stroke or heart death happened in 12.2% vs 13.1%. Tirzepatide was shown to be at least as good as dulaglutide, but not proven better. In other words, the trial showed it was not worse than dulaglutide at preventing these events. It did not show that it was better. ^{R2, R7}

Is it safe?

Its safety profile is well studied for the approved products, used as labeled. The FDA labels warn about: ^R4 - Caution Boxed warning, thyroid C-cell tumors: tirzepatide caused thyroid C-cell tumors in rats. Whether it does in people is unknown. Don't use it with a personal or family history of medullary thyroid cancer (MTC) or MEN 2. Watch for a neck lump, trouble swallowing, shortness of breath or lasting hoarseness. - Caution Pancreatitis: seen with GLP-1 drugs and tirzepatide. Severe stomach pain needs urgent care. The label says to stop if pancreatitis is suspected. - Caution Gallbladder disease: happened in clinical trials. - Caution Also on the label: low blood sugar (mainly with insulin or sulfonylureas), serious allergic reactions, kidney injury from dehydration, severe stomach side effects, worsening diabetic eye disease in people who already have it, and risk of inhaling stomach contents during anesthesia or deep sedation. - Caution Stopping early: in SURMOUNT-1, more people on tirzepatide than on placebo stopped early because of side effects (4.3% to 7.1% across doses vs 2.6%). ^R2

Compounded and gray-market tirzepatide: extra risks

FDA reports adverse events (problems reported after use, which may or may not have been caused by the drug) with compounded tirzepatide, some serious. ^R10

• Doses beyond the label. FDA has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide in doses beyond the FDA-approved label: more per dose, more often, or increased faster. Some of those patients reported seeking medical care for nausea, vomiting, diarrhea, stomach pain and constipation. ^R10
• Measuring mistakes. FDA's reports of hospitalizations from patients drawing up 5 to 20 times the intended amount from multi-dose vials involved compounded semaglutide, and the same "units" vs. mg problem applies to any vial dosed with an insulin syringe (tirzepatide's ~5-day half-life means an overdose can require prolonged observation; ^R7). See the measuring-mistakes section on our semaglutide page. ^{R9, R10}
• Reports so far. As of May 31, 2026, FDA had received more than 730 adverse event reports for compounded tirzepatide, and it notes these are likely under-reported. ^R10
• Fake and "research" products. FDA is aware of fake compounded tirzepatide. The labels name pharmacies that don't exist or didn't make it. FDA has also warned companies selling tirzepatide labeled "for research purposes" or "not for human consumption." ^R10
• Not FDA-reviewed. Compounded drugs don't undergo FDA premarket review for safety, quality or effectiveness. Gray-market "research" vials have even fewer checks. ^R10

What we don't know

• Unknown What is actually in a given compounded or gray-market vial (strength, form, sterility)
• Unknown Whether the rat thyroid tumor finding applies to people (per the label)
• Unknown Long-term outcomes of off-label or unsupervised use

Is it legal?

FDA-approved as a prescription drug for the uses above. Compounded versions are not FDA-approved. FDA declared the tirzepatide injection shortage resolved on Dec 19, 2024. Its grace periods for compounding copies have ended (state-licensed pharmacies: ended after the court ruling of Mar 5, 2025; outsourcing facilities, or large-scale compounders: Mar 19, 2025). In April 2026, FDA also proposed removing tirzepatide from the list that outsourcing facilities can compound from. Tirzepatide is not named on WADA's 2026 Prohibited List. As of Oct 15, 2026. ^{R7, R8, R10}

What's in the vial?

Pharmacy-dispensed Mounjaro and Zepbound are made under FDA oversight. Gray-market "tirzepatide" is not. For counterfeit (fake) GLP-1 products, FDA warns they could contain the wrong ingredients, too little, too much or no active ingredient, or other harmful ingredients. We found no published lab study of online-bought tirzepatide. In a small study of semaglutide vials bought from illegal online pharmacies, all 3 vials held far more drug than labeled, had low purity, and contained bacterial toxins (endotoxin). ^{R10, R11} Under the Open Peptide Standard, a GLP-1 vial overfilled by more than 20% is a critical fail (draft threshold). See results at /tests/. A passing test covers one batch, tested on one date. It does not mean the compound itself is safe. ^R10

What do users report?

Self-report, not evidence.

Unknown TBD. We'll only list this once we can cite a public source.

Study details

^R2 Human Human studies

All four trials were funded by Eli Lilly, the maker.

Study	People	Route	Dose used	Follow-up	Reported	Limitations	Citation
SURMOUNT-1 (Jastreboff 2022), obesity/overweight without diabetes	2,539 (1:1:1:1)	Subcutaneous	5, 10 or 15 mg weekly (20-wk escalation)	72 wk	Weight −15.0% / −19.5% / −20.9% vs −3.1%; stopped for side effects 4.3% / 7.1% / 6.2% vs 2.6%	Sponsor-funded	PMID 35658024
SURPASS-2 (Frías 2021), type 2 diabetes	1,879 (1:1:1:1)	Subcutaneous	5, 10 or 15 mg weekly vs semaglutide 1 mg	40 wk	HbA1c −2.01 / −2.24 / −2.30 vs −1.86 points; serious adverse events 5–7% vs 3%	Open-label; sponsor-funded	PMID 34170647
SURPASS-CVOT (Nicholls 2025), T2D + atherosclerotic CV disease	13,299 randomized (13,165 analyzed), 1:1	Subcutaneous	Tirzepatide up to 15 mg vs dulaglutide 1.5 mg weekly	Median not in abstract; ~4 yr per follow-up analysis (PMID 42875024)	MACE 12.2% vs 13.1% (HR 0.92, 95.3% CI 0.83–1.01); non-inferior (P=0.003), not superior (P=0.09); more GI adverse events on tirzepatide	Active comparator; sponsor-funded	PMID 41406444
SURMOUNT-OSA (Malhotra 2024), moderate-to-severe OSA + obesity	469 total in two trials: 234 not using PAP, 235 using PAP (per Zepbound label; not in abstract)	Subcutaneous	Maximum tolerated dose, 10 or 15 mg weekly	52 wk	AHI −25.3 vs −5.3 (trial 1); −29.3 vs −5.5 (trial 2) events/hr	Sponsor-funded	PMID 38912654

^{R4, R7} Label and regulatory (as of Oct 15, 2026)

• Dosing: approved dosing for Mounjaro and Zepbound is set by each prescribing label; see the labels: Mounjaro, Zepbound (DailyMed). Mounjaro label also reports SURPASS-CVOT: 13,299 patients randomized, active comparator.
• Both labels: overdose may need observation "taking into account the half-life of tirzepatide of approximately 5 days."
• ^R4 Boxed warning: risk of thyroid C-cell tumors (rats); contraindicated with personal/family history of MTC or MEN 2. Warnings: pancreatitis ("Discontinue if pancreatitis is suspected"), acute gallbladder disease, hypoglycemia, hypersensitivity, acute kidney injury (Mounjaro), severe GI reactions, diabetic retinopathy complications, pulmonary aspiration under anesthesia.

^{R9, R10} FDA compounding notices

• ^R9 FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (content current as of Jul 26, 2024). Semaglutide-specific; used here only for the "units" illustration.
• ^R10 FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026): doses beyond the label for compounded semaglutide or tirzepatide; "more than 730 reports of adverse events associated with compounded tirzepatide" as of May 31, 2026; fraudulent compounded tirzepatide; "research purposes" warnings.
• ^R10 Shortage and compounding: "[12/19/2024] ... FDA has issued a new decision determining the tirzepatide injection shortage is resolved." [3/10/2025] After the Mar 5, 2025 court ruling, for 503A pharmacies "the period of enforcement discretion ... has ended"; for 503B outsourcing facilities, until Mar 19, 2025 (FDA statement, content current as of Apr 1, 2026). On Apr 30, 2026 FDA proposed excluding tirzepatide from the 503B bulks list, comments due Jun 29, 2026 (FDA press release). The comment period was extended to Jul 30, 2026 (Federal Register, Jun 26, 2026). UNVERIFIED No final determination found as of Oct 15, 2026 (FDA.gov and Federal Register search; absence not proof).
• ^R8 WADA: tirzepatide is not named on the 2026 Prohibited List (checked against the official PDF). As an approved medicine it is not covered by S0. Unknown Not checked: WADA's 2026 Monitoring Program and the 2027 list.
• ^R10 Counterfeits: FDA warns that counterfeit products "could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients."
• ^R11 Online-purchase testing (semaglutide): Ashraf AR, et al. J Med Internet Res. 2024;26:e65440. doi:10.2196/65440. PMID 39509151. Three vials bought from illegal online pharmacies: semaglutide content 28.56%–38.69% above label; purity 7.7%–14.37% vs 99% claimed; no peptide-like impurities identified; no viable microbes; endotoxin detected in all samples (2.1645–8.9511 EU/mg). Very small sample (3 vials). Heavy metals: not reported in the abstract.

Full reference list (all verified on PubMed, Oct 15, 2026)

• Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024
• Frías JP, et al. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647
• Nicholls SJ, et al. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928. PMID 41406444
• Nicholls SJ, et al. Eur J Prev Cardiol. 2026 (online ahead of print). doi:10.1093/eurjpc/zwag452. PMID 42875024
• Ashraf AR, et al. J Med Internet Res. 2024;26:e65440. doi:10.2196/65440. PMID 39509151
• Malhotra A, et al. N Engl J Med. 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881. PMID 38912654

---

Disclaimer

This page is for education and harm reduction. It is not medical advice and not a recommendation to use tirzepatide outside a prescription. Please talk to a clinician you trust, especially if you have a personal or family history of thyroid cancer or MEN 2, have had pancreatitis or gallbladder disease, have diabetic eye disease, take insulin, or are pregnant. Seek care right away for severe stomach pain or repeated vomiting, and report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).